Comparing the current results to its competitors, Rani Therapeutics Holdings Inc reported Revenue increase in the 1 quarter 2026 by 893.02 % year on year. The sales growth was above Rani Therapeutics Holdings Inc 's competitors' average revenue growth of 79.35 %, achieved in the same quarter.
Rani Therapeutics Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 596.33 %
Due to outstanding performance in Overall company, revenue grew by 893.02 % Rani Therapeutics Holdings Inc improved its market share, to approximately 0 %.
October 17, 2025
SAN JOSE, Calif., Oct. 17, 2025 Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a pioneering clinical-stage biotherapeutics company dedicated to the oral delivery of biologics and pharmaceuticals, has officially announced a strategic partnership with Chugai Pharmaceutical Co., Ltd. The collaboration, which is valued at up to $1.085 billion, encompasses the development and commercialization of innovative therapies, focusing on Rani s oral delivery technology paired with Chugai s promising rare disease antibody.The deal is expected to advance Rani s proprietary RaniPill® technology, designed to facilitate the oral administration of biologics, a challenge that has long impeded the efficacy and convenience o...
October 8, 2024
In the ever-evolving landscape of biotherapeutics, Rani Therapeutics Holdings, Inc. stands out as a pioneer dedicated to advancing the oral delivery of biologics and pharmaceuticals. As a clinical-stage company, Rani is committed to revolutionizing the way patients access life-saving medications. This commitment will be in the spotlight during the 2024 Maxim Healthcare Virtual Summit, scheduled for October 17, 2024, where Rani Therapeutics’ leadership will engage with industry stakeholders on pivotal discussions regarding the future of drug delivery systems.Rani Therapeutics has announced that its Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in an engagi...
June 24, 2024
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentIn an exciting development for the pharmaceutical industry, Rani Therapeutics has announced a partnership with ProGen to collaborate on the development of a groundbreaking oral obesity treatment. The innovative RT-114 obesity program aims to combine ProGen s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with Rani Therapeutics game-changing RaniPill capsule. This collaboration brings together two pioneers in the field, with each company contributing its unique expertise to revolutionize the way obesity is treated.The key differentiating factor of this program lies in the RaniPill capsule, which has be...
In a significant advancement in oral drug delivery, Rani Therapeutics, a pioneer in oral biologics, has revealed compelling preclinical pharmacodynamic data on the transenteric delivery of GLP-1 Incretin Triagonist. This disclosure underscores the immense potential of Rani s cutting-edge drug delivery technology to revolutionize the treatment of metabolic diseases, dramatically transforming the prospects for the company. Transenteric delivery pertains to a novel drug administration method wherein drugs are delivered transversely through the intestinal wall, bypassing the traditional oral route. In the recent preclinical study, the transenteric delivery of the incretin triagonist of GLP-1, GIP, and g...
Publicly Traded Peers of Rani Therapeutics Holdings Inc
Amarin Corp Plcuk Share Performance
-7.44%
One Year
Amarin Corp Plcuk
Profile
Amarin Corp Plcuk's business model revolves around the development, commercialization, and marketing of innovative pharmaceutical products, particularly focused on cardiovascular health.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Progyny Inc is a company that operates as a fertility benefits management platform, offering comprehensive fertility solutions to employers and their employees.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Sources:
Rani Therapeutics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rani Therapeutics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
